Lenvatinib price after medical insurance reimbursement in 2023

Lenvatinib is approved for use alone or in combination with other drugs to treat advanced endometrial cancer that has progressed after other systemic treatments, along with pembrolizumab in patients whose cancer is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and cannot be treated with surgery or radiation therapy. Lenvatinib is also used in a type of liver cancer called hepatocellular carcinoma, where it is used as the first treatment for patients whose cancer cannot be removed with surgery. Lenvatinib is also indicated in a type of advanced renal cell carcinoma, a type of renal cell carcinoma, and may be given with everolimus in adults receiving an angiogenesis inhibitor, or in adults with pembrolizumab as the first treatment option. Lenvatinib may also be used for thyroid cancer in some patients whose cancer has worsened, come back, or has spread to other parts of the body and has not responded to radioactive iodine treatment.

Lenvatinib The original drug has been launched in China and has entered the scope of Class B medical insurance. Specifications The price of 4mg*30 tablets per box may be more than 3,000 yuan. The reimbursement ratio is different in different regions. The price after reimbursement may be different. Please consult the local medical insurance bureau and other places for details. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be RMB 800 (the price may fluctuate due to exchange rates).